Work

Comment: Assessing humoral immunocompetence after alemtuzumab treatment in MS

Year: 2013

Type: article

Abstract: Alemtuzumab, a humanized monoclonal antibody, depletes CD52+ circulating leukocytes. In humans, this includes most mononuclear leukocytes. Exciting results from 2 phase III trials established the superiority of alemtuzumab in reducing multiple sclerosis (MS) relapse rate compared with high-dose interferon-β.1 Increased mild to moderate infections occurred in both trials in the alemtuzumab compared to interferon-β arms. Also noteworthy, secondary autoimmune diseases develop in a sizeable proportion of alemtuzumab-treated patients.

Source: Neurology

DOI: 10.1212/wnl.0b013e3182a352c6

Authors: Anne H. Cross, Robyn S. Klein

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institute of Neurological Disorders and Stroke

Award: Biomarkers and Pathogenesis of MS: From Mouse to Human